Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
28 avr. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
26 oct. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Tauriga Sciences, Inc. Receives Notice of Allowance from the European Union Intellectual Property Office - Registering its Trademark for Tauri-Gummies
03 août 2020 09h15 HE
|
Tauriga Sciences
NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a...
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
11 sept. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Brazil Issues Vystar Patent Notice of Allowance for Deproteinization of Vytex Natural Rubber Latex
05 août 2019 08h36 HE
|
Vystar Corp
WORCESTER, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Vystar Corp. (OTC Market: VYST) has received a notice of allowance from Brazil for a patent titled “Natural Rubber Latex Having Reduced...
Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
15 juil. 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...
IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm™ Patent
05 juil. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 05, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) (“IntelGenx” or the “Company”), a leading oral drug delivery company primarily focused on the...